An unsolicited acquisition proposal for InMode lapsed without agreement, ending speculation about a forced sale and leaving the company to navigate growth independently. The failed bid removes a near-term catalyst and leaves InMode stock vulnerable to execution risk and competitive pressure in the RF microneedling and body contouring device space.
Business & M&A
InMode Takeover Bid Lapses—Stock Faces Pressure Without Deal
An unsolicited acquisition proposal for InMode expired without a deal, leaving the RF microneedling and energy-device maker to execute standalone.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
InMode takeover bid expires, leaving the RF microneedling maker to execute standalone.
For practices, this means InMode remains a standalone player—no new ownership, no strategic pivot, no forced asset sales. The company will continue competing on Morpheus8 innovation and market share. The stock pressure is real, but the device portfolio (Morpheus8, Lumenis legacy products, and recent cooling-module additions) remains clinically sound. Practices holding InMode equipment should expect the company to defend market position through pricing discipline and clinical evidence rather than M&A.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.